JP2006500910A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006500910A5 JP2006500910A5 JP2003584309A JP2003584309A JP2006500910A5 JP 2006500910 A5 JP2006500910 A5 JP 2006500910A5 JP 2003584309 A JP2003584309 A JP 2003584309A JP 2003584309 A JP2003584309 A JP 2003584309A JP 2006500910 A5 JP2006500910 A5 JP 2006500910A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid molecule
- disease
- cell
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 87
- 108020004707 nucleic acids Proteins 0.000 claims 50
- 102000039446 nucleic acids Human genes 0.000 claims 50
- 150000007523 nucleic acids Chemical class 0.000 claims 50
- 210000004027 cell Anatomy 0.000 claims 34
- 201000010099 disease Diseases 0.000 claims 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 30
- 108090000623 proteins and genes Proteins 0.000 claims 28
- 229920001184 polypeptide Polymers 0.000 claims 19
- 102000004196 processed proteins & peptides Human genes 0.000 claims 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims 19
- 230000014509 gene expression Effects 0.000 claims 17
- 238000012360 testing method Methods 0.000 claims 15
- 150000001875 compounds Chemical class 0.000 claims 13
- 239000000203 mixture Substances 0.000 claims 11
- 239000000126 substance Substances 0.000 claims 11
- 239000003112 inhibitor Substances 0.000 claims 10
- 102000004169 proteins and genes Human genes 0.000 claims 10
- 210000003169 central nervous system Anatomy 0.000 claims 9
- 230000000694 effects Effects 0.000 claims 9
- 239000000523 sample Substances 0.000 claims 9
- 239000002773 nucleotide Substances 0.000 claims 8
- 125000003729 nucleotide group Chemical group 0.000 claims 8
- 210000001519 tissue Anatomy 0.000 claims 8
- 241001465754 Metazoa Species 0.000 claims 7
- 239000005557 antagonist Substances 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 7
- 230000033115 angiogenesis Effects 0.000 claims 6
- 230000008859 change Effects 0.000 claims 6
- 210000003583 retinal pigment epithelium Anatomy 0.000 claims 5
- 206010029113 Neovascularisation Diseases 0.000 claims 4
- 108091005461 Nucleic proteins Proteins 0.000 claims 4
- 230000002159 abnormal effect Effects 0.000 claims 4
- 210000004155 blood-retinal barrier Anatomy 0.000 claims 4
- 230000004378 blood-retinal barrier Effects 0.000 claims 4
- 239000002299 complementary DNA Substances 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 108020004999 messenger RNA Proteins 0.000 claims 4
- 230000035882 stress Effects 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 3
- 230000008499 blood brain barrier function Effects 0.000 claims 3
- 210000001218 blood-brain barrier Anatomy 0.000 claims 3
- 230000000295 complement effect Effects 0.000 claims 3
- 238000012258 culturing Methods 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 208000030533 eye disease Diseases 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 229940127557 pharmaceutical product Drugs 0.000 claims 3
- 230000009120 phenotypic response Effects 0.000 claims 3
- 229940002612 prodrug Drugs 0.000 claims 3
- 239000000651 prodrug Substances 0.000 claims 3
- 208000017442 Retinal disease Diseases 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 238000004113 cell culture Methods 0.000 claims 2
- 239000013592 cell lysate Substances 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 210000001508 eye Anatomy 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 150000002611 lead compounds Chemical class 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 239000002547 new drug Substances 0.000 claims 2
- 230000002207 retinal effect Effects 0.000 claims 2
- 210000004358 rod cell outer segment Anatomy 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 108091027075 5S-rRNA precursor Proteins 0.000 claims 1
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 230000006820 DNA synthesis Effects 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 238000012286 ELISA Assay Methods 0.000 claims 1
- 102100031103 Geranylgeranyl transferase type-2 subunit beta Human genes 0.000 claims 1
- 101100243742 Homo sapiens RABGGTB gene Proteins 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 208000022873 Ocular disease Diseases 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims 1
- 108091028664 Ribonucleotide Proteins 0.000 claims 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- 238000007792 addition Methods 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 210000004102 animal cell Anatomy 0.000 claims 1
- 239000012805 animal sample Substances 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 230000033228 biological regulation Effects 0.000 claims 1
- 210000005252 bulbus oculi Anatomy 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 230000012292 cell migration Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 230000010002 chemokinesis Effects 0.000 claims 1
- 230000035605 chemotaxis Effects 0.000 claims 1
- 238000010367 cloning Methods 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 230000003412 degenerative effect Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 238000007876 drug discovery Methods 0.000 claims 1
- 238000001962 electrophoresis Methods 0.000 claims 1
- 210000002889 endothelial cell Anatomy 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 239000003889 eye drop Substances 0.000 claims 1
- 229940012356 eye drops Drugs 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- 238000001502 gel electrophoresis Methods 0.000 claims 1
- 230000009368 gene silencing by RNA Effects 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 238000009396 hybridization Methods 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 230000001146 hypoxic effect Effects 0.000 claims 1
- 238000003119 immunoblot Methods 0.000 claims 1
- 238000005468 ion implantation Methods 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 239000003607 modifier Substances 0.000 claims 1
- 230000035764 nutrition Effects 0.000 claims 1
- 235000016709 nutrition Nutrition 0.000 claims 1
- 230000008520 organization Effects 0.000 claims 1
- 230000036542 oxidative stress Effects 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 230000001991 pathophysiological effect Effects 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000008569 process Effects 0.000 claims 1
- 230000026447 protein localization Effects 0.000 claims 1
- 238000003753 real-time PCR Methods 0.000 claims 1
- 108091008146 restriction endonucleases Proteins 0.000 claims 1
- 210000001525 retina Anatomy 0.000 claims 1
- 239000002336 ribonucleotide Substances 0.000 claims 1
- 125000002652 ribonucleotide group Chemical group 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 238000012163 sequencing technique Methods 0.000 claims 1
- 238000004513 sizing Methods 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 230000000392 somatic effect Effects 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- 238000007910 systemic administration Methods 0.000 claims 1
- 230000006459 vascular development Effects 0.000 claims 1
- 230000035899 viability Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02008761 | 2002-04-18 | ||
| US43117302P | 2002-12-05 | 2002-12-05 | |
| PCT/EP2003/004003 WO2003087368A2 (en) | 2002-04-18 | 2003-04-16 | Means and methods for the specific modulation of target genes in the cns and the eye and methods for their identification |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006500910A JP2006500910A (ja) | 2006-01-12 |
| JP2006500910A5 true JP2006500910A5 (cg-RX-API-DMAC10.html) | 2006-06-15 |
Family
ID=47711411
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003584309A Pending JP2006500910A (ja) | 2002-04-18 | 2003-04-16 | Ｃｎｓと眼の標的遺伝子を特異的に調節するための手段と方法及びその同定法 |
| JP2003584308A Expired - Fee Related JP5578388B2 (ja) | 2002-04-18 | 2003-04-16 | 中枢神経システム及び／若しくは眼の細胞及び組織中の遺伝子の特異的阻害のための手段と方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003584308A Expired - Fee Related JP5578388B2 (ja) | 2002-04-18 | 2003-04-16 | 中枢神経システム及び／若しくは眼の細胞及び組織中の遺伝子の特異的阻害のための手段と方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (5) | US20050222061A1 (cg-RX-API-DMAC10.html) |
| EP (2) | EP1495120B1 (cg-RX-API-DMAC10.html) |
| JP (2) | JP2006500910A (cg-RX-API-DMAC10.html) |
| AU (3) | AU2003222820A1 (cg-RX-API-DMAC10.html) |
| CA (2) | CA2482903A1 (cg-RX-API-DMAC10.html) |
| ES (1) | ES2397060T3 (cg-RX-API-DMAC10.html) |
| MX (2) | MXPA04010282A (cg-RX-API-DMAC10.html) |
| WO (2) | WO2003087367A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050222061A1 (en) | 2002-04-18 | 2005-10-06 | Schulte Ralf W | Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye |
| US7148342B2 (en) | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
| US7794704B2 (en) | 2004-01-23 | 2010-09-14 | Advanced Cell Technology, Inc. | Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration |
| CA2937099A1 (en) * | 2004-01-23 | 2005-08-04 | Astellas Institute For Regenerative Medicine | Improved modalities for the treatment of degenerative diseases of the retina |
| GB0418762D0 (en) * | 2004-08-23 | 2004-09-22 | Genomica Sau | Methods and compositions to treat glaucoma |
| DK1781787T3 (en) | 2004-08-23 | 2017-07-31 | Sylentis Sau | TREATMENT OF EYE DISORDERS FEATURED BY AN INCREASED INTRAOCULAR PRESSURE WITH SIRNAS |
| TW200639253A (en) * | 2005-02-01 | 2006-11-16 | Alcon Inc | RNAi-mediated inhibition of ocular targets |
| GB0521351D0 (en) | 2005-10-20 | 2005-11-30 | Genomica Sau | Modulation of TRPV expression levels |
| GB0521716D0 (en) | 2005-10-25 | 2005-11-30 | Genomica Sau | Modulation of 11beta-hydroxysteriod dehydrogenase 1 expression for the treatment of ocular diseases |
| GB0605337D0 (en) | 2006-03-17 | 2006-04-26 | Genomica Sau | Treatment of CNS conditions |
| US20090130212A1 (en) * | 2006-05-15 | 2009-05-21 | Physical Pharmaceutica, Llc | Composition and improved method for preparation of small particles |
| JP2009540011A (ja) * | 2006-06-12 | 2009-11-19 | エクセジェニックス、インク．ディー／ビー／エー オプコ ヘルス、インク． | 血管新生のｓｉＲＮＡ阻害のための組成物及び方法 |
| JP2010500011A (ja) | 2006-08-08 | 2010-01-07 | ガンサー ハートマン | ５’リン酸オリゴヌクレオチドの構造および使用 |
| US7872118B2 (en) * | 2006-09-08 | 2011-01-18 | Opko Ophthalmics, Llc | siRNA and methods of manufacture |
| JP2010507387A (ja) | 2006-10-25 | 2010-03-11 | クアーク・ファーマスーティカルス、インコーポレイテッド | 新規のｓｉＲＮＡおよびその使用方法 |
| CA2701845A1 (en) | 2007-10-03 | 2009-04-09 | Quark Pharmaceuticals, Inc. | Novel sirna structures |
| EP2209888B1 (en) | 2007-10-12 | 2019-12-04 | Astellas Institute for Regenerative Medicine | Improved methods of producing rpe cells and compositions of rpe cells |
| US9738680B2 (en) | 2008-05-21 | 2017-08-22 | Rheinische Friedrich-Wilhelms-Universität Bonn | 5′ triphosphate oligonucleotide with blunt end and uses thereof |
| EP2342340A1 (en) | 2008-09-22 | 2011-07-13 | Rxi Pharmaceuticals Corporation | Rna interference in skin indications |
| JP5832293B2 (ja) | 2008-12-04 | 2015-12-16 | オプコ ファーマシューティカルズ、エルエルシー | 血管新生促進ｖｅｇｆイソ型を選択的に抑制する組成物および方法 |
| US20110288155A1 (en) | 2008-12-18 | 2011-11-24 | Elena Feinstein | Sirna compounds and methods of use thereof |
| WO2010090762A1 (en) | 2009-02-04 | 2010-08-12 | Rxi Pharmaceuticals Corporation | Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
| IL281453B (en) | 2009-11-17 | 2022-07-01 | Astellas Inst For Regenerative Medicine | Methods for preparing human rpe cells and pharmaceutical preparations of human rpe cells |
| WO2011072091A1 (en) * | 2009-12-09 | 2011-06-16 | Quark Pharmaceuticals, Inc. | Methods and compositions for treating diseases, disorders or injury of the cns |
| WO2011119852A1 (en) | 2010-03-24 | 2011-09-29 | Rxi Pharmaceuticals Corporation | Reduced size self-delivering rnai compounds |
| US9095504B2 (en) | 2010-03-24 | 2015-08-04 | Rxi Pharmaceuticals Corporation | RNA interference in ocular indications |
| US8648053B2 (en) | 2010-10-20 | 2014-02-11 | Rosalind Franklin University Of Medicine And Science | Antisense oligonucleotides that target a cryptic splice site in Ush1c as a therapeutic for Usher syndrome |
| CA2822261A1 (en) * | 2010-12-23 | 2012-06-28 | Laurent Alexandre | Method to obtain optical means adapted to a human individual suffering or susceptible to suffer from one or more genetic related eye disorder(s) or disease(s) |
| EP2508530A1 (en) | 2011-03-28 | 2012-10-10 | Rheinische Friedrich-Wilhelms-Universität Bonn | Purification of triphosphorylated oligonucleotides using capture tags |
| WO2012151324A1 (en) * | 2011-05-02 | 2012-11-08 | Isis Pharmaceuticals, Inc. | Antisense compounds targeting genes associated with usher syndrome |
| US10314594B2 (en) | 2012-12-14 | 2019-06-11 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
| US10307167B2 (en) | 2012-12-14 | 2019-06-04 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
| US10813630B2 (en) | 2011-08-09 | 2020-10-27 | Corquest Medical, Inc. | Closure system for atrial wall |
| AU2012389270B2 (en) | 2012-09-05 | 2018-11-08 | Sylentis S.A.U. | siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions |
| GB201215857D0 (en) | 2012-09-05 | 2012-10-24 | Sylentis Sau | siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions |
| EP2712870A1 (en) | 2012-09-27 | 2014-04-02 | Rheinische Friedrich-Wilhelms-Universität Bonn | Novel RIG-I ligands and methods for producing them |
| US20140142689A1 (en) | 2012-11-21 | 2014-05-22 | Didier De Canniere | Device and method of treating heart valve malfunction |
| US9566443B2 (en) | 2013-11-26 | 2017-02-14 | Corquest Medical, Inc. | System for treating heart valve malfunction including mitral regurgitation |
| JP7180964B2 (ja) * | 2014-01-17 | 2022-11-30 | ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク | 三次元イメージング装置および方法 |
| US10061111B2 (en) | 2014-01-17 | 2018-08-28 | The Trustees Of Columbia University In The City Of New York | Systems and methods for three dimensional imaging |
| WO2015132303A1 (en) | 2014-03-04 | 2015-09-11 | Sylentis Sau | Sirnas and their use in methods and compositions for the treatment and/or prevention of eye conditions |
| CA2947270A1 (en) | 2014-04-28 | 2015-11-05 | Rxi Pharmaceuticals Corporation | Methods for treating cancer using nucleic acids targeting mdm2 or mycn |
| EP3188799B1 (en) | 2014-09-05 | 2022-07-06 | Phio Pharmaceuticals Corp. | Methods for treating aging and skin disorders using nucleic acids targeting tyr or mmp1 |
| US10842626B2 (en) | 2014-12-09 | 2020-11-24 | Didier De Canniere | Intracardiac device to correct mitral regurgitation |
| WO2016140921A1 (en) | 2015-03-02 | 2016-09-09 | 180 Therapeutics Lp | Method of treating a localized fibrotic disorder using an il-33 antagonist |
| KR20170095417A (ko) * | 2016-02-11 | 2017-08-23 | 삼성전자주식회사 | 발광 장치 및 전자 기기 |
| EP3482238B1 (en) | 2016-07-10 | 2024-12-18 | The Trustees of Columbia University in the City of New York | Three-dimensional imaging using swept, confocally aligned planar excitation with an image relay |
| US10712545B2 (en) * | 2017-03-07 | 2020-07-14 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Systems and methods for conducting contact-free thickness and refractive-index measurements of intraocular lenses using a self-calibrating dual confocal microscopy system |
| JP7167059B2 (ja) | 2017-04-19 | 2022-11-08 | フィオ ファーマシューティカルズ コーポレーション | 核酸化合物の局所送達 |
| CN108739556A (zh) * | 2018-08-31 | 2018-11-06 | 南京工业大学 | 一种光化学诱导斑马鱼缺血性脑卒中模型的应用 |
| CN119524137B (zh) * | 2024-12-11 | 2026-06-05 | 徐州医科大学 | Fbxo22在诊断、治疗非酒精性脂肪性肝病中的应用 |
Family Cites Families (100)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) * | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5019369A (en) * | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US5550289A (en) * | 1985-01-07 | 1996-08-27 | Syntex (U.S.A.) Inc. | N-(1,(1-1)-dialkyloxy)-and N-(1,(1-1)-dialkenyloxy alk-1-yl-N-N,N-tetrasubstituted ammonium lipids and uses therefor |
| US5139941A (en) * | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| US4837028A (en) * | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US4920016A (en) * | 1986-12-24 | 1990-04-24 | Linear Technology, Inc. | Liposomes with enhanced circulation time |
| US5712257A (en) * | 1987-08-12 | 1998-01-27 | Hem Research, Inc. | Topically active compositions of mismatched dsRNAs |
| IE72103B1 (en) | 1987-08-12 | 1997-03-12 | Hem Res Inc | Promotion of host defense by systemic dsRNA treatment |
| US5683986A (en) * | 1987-08-12 | 1997-11-04 | Hemispherx Biopharma Inc. | Elaboration of host defense mediators into biological fluids by systemic dsRNA treatment |
| US5498521A (en) * | 1990-01-24 | 1996-03-12 | President And Fellows Of Harvard College | Diagnosis of hereditary retinal degenerative diseases |
| US5843738A (en) * | 1990-08-14 | 1998-12-01 | Isis Pharmaceuticals, Inc. | Oligonucleotide modulation of cell adhesion |
| US5252479A (en) * | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
| US5587308A (en) | 1992-06-02 | 1996-12-24 | The United States Of America As Represented By The Department Of Health & Human Services | Modified adeno-associated virus vector capable of expression from a novel promoter |
| DE69334238D1 (de) | 1992-09-25 | 2008-09-25 | Aventis Pharma Sa | Adenovirus vektoren für die übertragung fremder gene in zellen des zentralen nervensystems, insbesondere im gehirn |
| US6177401B1 (en) * | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
| US5478745A (en) | 1992-12-04 | 1995-12-26 | University Of Pittsburgh | Recombinant viral vector system |
| GB9308271D0 (en) | 1993-04-21 | 1993-06-02 | Univ Edinburgh | Method of isolating and/or enriching and/or selectively propagating pluripotential animal cells and animals for use in said method |
| US5639872A (en) * | 1993-07-27 | 1997-06-17 | Hybridon, Inc. | Human VEGF-specific oligonucleotides |
| US5731294A (en) * | 1993-07-27 | 1998-03-24 | Hybridon, Inc. | Inhibition of neovasularization using VEGF-specific oligonucleotides |
| US6410322B1 (en) | 1993-07-27 | 2002-06-25 | Hybridon Inc | Antisense oligonucleotide inhibition of vascular endothelial growth factor expression |
| US5624803A (en) * | 1993-10-14 | 1997-04-29 | The Regents Of The University Of California | In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom |
| US6037329A (en) * | 1994-03-15 | 2000-03-14 | Selective Genetics, Inc. | Compositions containing nucleic acids and ligands for therapeutic treatment |
| EP0769552A4 (en) * | 1994-06-27 | 1997-06-18 | Toagosei Co Ltd | 'ANTISENSE'NUCLEIC ACID COMPOSITION |
| US5882914A (en) * | 1995-06-06 | 1999-03-16 | The Johns Hopkins University School Of Medicine | Nucleic acids encoding the hypoxia inducible factor-1 |
| US20030216335A1 (en) * | 2001-11-30 | 2003-11-20 | Jennifer Lockridge | Method and reagent for the modulation of female reproductive diseases and conditions |
| WO1997018855A1 (en) * | 1995-11-21 | 1997-05-29 | Eduard Naumovich Lerner | Device for enhanced delivery of biologically active substances and compounds in an organism |
| GB9524807D0 (en) * | 1995-12-05 | 1996-02-07 | Smithkline Beecham Plc | Novel compounds |
| US5843016A (en) * | 1996-03-18 | 1998-12-01 | Physion S.R.L. | Electromotive drug administration for treatment of acute urinary outflow obstruction |
| US7033598B2 (en) * | 1996-11-19 | 2006-04-25 | Intrabrain International N.V. | Methods and apparatus for enhanced and controlled delivery of a biologically active agent into the central nervous system of a mammal |
| US6165709A (en) * | 1997-02-28 | 2000-12-26 | Fred Hutchinson Cancer Research Center | Methods for drug target screening |
| US20050096282A1 (en) * | 1997-04-21 | 2005-05-05 | Lewin Alfred S. | Adeno-associated virus-delivered ribozyme compositions and methods for the treatment of retinal diseases |
| NZ500427A (en) | 1997-04-21 | 2002-12-20 | Univ Florida | The use of ribozyme treatment for retinal diseases |
| ATE261721T1 (de) * | 1997-06-13 | 2004-04-15 | Nanopharm Ag | System zur gezielten wirkstoffzufuhr, verfahren zu seiner herstellung und verwendung |
| US5902598A (en) * | 1997-08-28 | 1999-05-11 | Control Delivery Systems, Inc. | Sustained release drug delivery devices |
| US6440933B1 (en) | 1997-09-10 | 2002-08-27 | University Of Florida | Compounds and method for the prevention and treatment of diabetic retinopathy |
| US6506559B1 (en) * | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| US20030096775A1 (en) | 2001-10-23 | 2003-05-22 | Isis Pharmaceuticals Inc. | Antisense modulation of complement component C3 expression |
| US6433145B1 (en) * | 1998-07-21 | 2002-08-13 | Human Genome Sciences, Inc. | Keratinocyte derived interferon |
| EP0979869A1 (en) | 1998-08-07 | 2000-02-16 | Hoechst Marion Roussel Deutschland GmbH | Short oligonucleotides for the inhibition of VEGF expression |
| US6219557B1 (en) * | 1998-12-11 | 2001-04-17 | Ericsson Inc. | System and method for providing location services in parallel to existing services in general packet radio services architecture |
| AU776150B2 (en) * | 1999-01-28 | 2004-08-26 | Medical College Of Georgia Research Institute, Inc. | Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| US6355271B1 (en) * | 1999-02-03 | 2002-03-12 | Biosante Pharmaceuticals, Inc. | Therapeutic calcium phosphate particles and methods of manufacture and use |
| US6121000A (en) * | 1999-02-11 | 2000-09-19 | Genesense Technologies, Inc. | Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase |
| IL145778A0 (en) * | 1999-04-21 | 2002-07-25 | American Home Prod | Methods and compositions for inhibiting the function of polynucleotide sequences |
| US6331313B1 (en) * | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
| GB9927444D0 (en) * | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| CN101353658A (zh) * | 1999-12-16 | 2009-01-28 | 孟山都技术有限公司 | 新型植物表达构建物 |
| AU2925401A (en) | 2000-01-19 | 2001-07-31 | Parkash S Gill | Methods and compositions for antisense vegf oligonucleotides |
| WO2001057206A2 (en) | 2000-02-03 | 2001-08-09 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for the inhibition of checkpoint kinase-1 (chk 1) enzyme |
| JP2003526367A (ja) | 2000-03-16 | 2003-09-09 | ジェネティカ インコーポレイテッド | Ｒｎａ干渉の方法とｒｎａ干渉組成物 |
| KR20080023768A (ko) * | 2000-03-30 | 2008-03-14 | 화이트헤드 인스티튜트 포 바이오메디칼 리서치 | Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체 |
| US6372250B1 (en) * | 2000-04-25 | 2002-04-16 | The Regents Of The University Of California | Non-invasive gene targeting to the brain |
| US6375972B1 (en) * | 2000-04-26 | 2002-04-23 | Control Delivery Systems, Inc. | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
| AU2001295193A1 (en) * | 2000-05-01 | 2001-11-12 | Novartis Ag | Vectors for ocular transduction and use thereof for genetic therapy |
| JP2004520261A (ja) | 2000-06-23 | 2004-07-08 | イシウム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ イエルサレム | 改善された性質を有する正電荷を有するペプチド核酸類縁体 |
| US6852510B2 (en) * | 2000-07-03 | 2005-02-08 | Gala Design Inc | Host cells containing multiple integrating vectors |
| WO2002008242A1 (en) * | 2000-07-21 | 2002-01-31 | The Trustees Of Columbia University In The City Of New York | Nucleic acids comprising regions of the rat peg-3 promoter and uses thereof |
| IL137672A0 (en) | 2000-08-03 | 2001-10-31 | Dpharm Ltd | Derivatives of branched-chain lipophilic molecules and uses thereof |
| US6443145B1 (en) * | 2000-08-25 | 2002-09-03 | Learning Legacy | Solar seeker |
| US20020132788A1 (en) * | 2000-11-06 | 2002-09-19 | David Lewis | Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo |
| US20020173478A1 (en) * | 2000-11-14 | 2002-11-21 | The Trustees Of The University Of Pennsylvania | Post-transcriptional gene silencing by RNAi in mammalian cells |
| CN100523215C (zh) | 2000-12-01 | 2009-08-05 | 马普科技促进协会 | 介导rna干涉的小rna分子 |
| US20020132257A1 (en) | 2001-01-31 | 2002-09-19 | Tony Giordano | Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell |
| US20020165158A1 (en) * | 2001-03-27 | 2002-11-07 | King George L. | Methods of modulating angiogenesis |
| JP2002305193A (ja) * | 2001-04-05 | 2002-10-18 | Sony Corp | 半導体装置とその製造方法 |
| US20030045830A1 (en) * | 2001-04-17 | 2003-03-06 | De Bizemont Therese | Gene therapy with chimeric oligonucleotides delivered by a method comprising a step of iontophoresis |
| US20050048529A1 (en) * | 2002-02-20 | 2005-03-03 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA) |
| US20050187174A1 (en) * | 2001-05-18 | 2005-08-25 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA) |
| US20050148530A1 (en) | 2002-02-20 | 2005-07-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| US20050159380A1 (en) * | 2001-05-18 | 2005-07-21 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of angiopoietin gene expression using short interfering nucleic acid (siNA) |
| US7517864B2 (en) | 2001-05-18 | 2009-04-14 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| WO2003070910A2 (en) | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Incorporated | INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| JP2005500025A (ja) | 2001-05-29 | 2005-01-06 | サーナ・セラピューティクス・インコーポレイテッド | 女性生殖疾病及び状態の核酸に基づく調節 |
| CN100564400C (zh) | 2001-05-29 | 2009-12-02 | 联合碳化化学及塑料技术有限责任公司 | 烯烃聚合催化剂组合物和制备方法 |
| WO2003010180A1 (en) * | 2001-07-23 | 2003-02-06 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for rnai mediated inhibition of gene expression in mammals |
| AU2002317333C1 (en) | 2001-08-01 | 2009-06-25 | University Of Bristol | VEGF isoform |
| AU2002348163A1 (en) * | 2001-11-02 | 2003-05-19 | Intradigm Corporation | Therapeutic methods for nucleic acid delivery vehicles |
| AU2002343792A1 (en) * | 2001-11-28 | 2003-06-10 | Center For Advanced Science And Technology Incubation, Ltd. | siRNA EXPRESSION SYSTEM AND PROCESS FOR PRODUCING FUNCTIONAL GENE-KNOCKDOWN CELLS AND THE LIKE USING THE SAME |
| ES2649817T3 (es) * | 2002-04-05 | 2018-01-15 | Roche Innovation Center Copenhagen A/S | Compuestos oligom¿¿ricos para la modulaci¿®n de la expresi¿®n de HIF-1¿Á |
| US20050222061A1 (en) | 2002-04-18 | 2005-10-06 | Schulte Ralf W | Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye |
| WO2003099298A1 (en) | 2002-05-24 | 2003-12-04 | Max-Planck Gesellschaft zur Förderung der Wissenschaften e.V. | Rna interference mediating small rna molecules |
| US20040115640A1 (en) * | 2002-12-11 | 2004-06-17 | Isis Pharmaceuticals Inc. | Modulation of angiopoietin-2 expression |
| US7148342B2 (en) | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
| SG166672A1 (en) | 2002-08-06 | 2010-12-29 | Intradigm Corp | Methods of down regulating target gene expression in vivo by introduction of interfering rna |
| WO2004042024A2 (en) * | 2002-11-01 | 2004-05-21 | The Trustees Of The University Of Pennsylvania | COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF HIF-1 ALPHA |
| EP2305813A3 (en) * | 2002-11-14 | 2012-03-28 | Dharmacon, Inc. | Fuctional and hyperfunctional sirna |
| JP2007524349A (ja) * | 2003-01-16 | 2007-08-30 | ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア | ＩＣＡＭ−１のｓｉＲＮＡ阻害のための組成物及び方法 |
| AU2004233043A1 (en) | 2003-04-18 | 2004-11-04 | The Trustees Of The University Of Pennsylvania | Compositions and methods for siRNA inhibition of angiopoietin 1 and 2 and their receptor Tie2 |
| US20050019927A1 (en) * | 2003-07-13 | 2005-01-27 | Markus Hildinger | DECREASING GENE EXPRESSION IN A MAMMALIAN SUBJECT IN VIVO VIA AAV-MEDIATED RNAi EXPRESSION CASSETTE TRANSFER |
| ES2423060T3 (es) * | 2004-03-12 | 2013-09-17 | Alnylam Pharmaceuticals, Inc. | Agentes iRNA que tienen como diana al VEGF |
| US20060182783A1 (en) * | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Sustained release intraocular drug delivery systems |
| TWI243957B (en) * | 2004-08-16 | 2005-11-21 | Asia Optical Co Inc | Assembling method of reticle module |
| JP2008537752A (ja) | 2005-04-12 | 2008-09-25 | イントラディグム コーポレイション | がんおよび他の新血管形成疾患を処置するためのＲＮＡｉ治療用の組成物および方法 |
| AU2006337093B2 (en) * | 2005-12-22 | 2013-03-14 | Opko Pharmaceuticals, Llc. | Compositions and methods for regulating complement system |
| WO2007085266A1 (en) * | 2006-01-30 | 2007-08-02 | Dako Denmark A/S | High-speed quantification of antigen specific t-cells in whole blood by flow cytometry |
| JP2009540011A (ja) | 2006-06-12 | 2009-11-19 | エクセジェニックス、インク．ディー／ビー／エー オプコ ヘルス、インク． | 血管新生のｓｉＲＮＡ阻害のための組成物及び方法 |
| US7872118B2 (en) | 2006-09-08 | 2011-01-18 | Opko Ophthalmics, Llc | siRNA and methods of manufacture |
| GB0704678D0 (en) | 2007-03-09 | 2007-04-18 | Univ Bristol | Pro- and anti-angiogenic treatments |
-
2003
- 2003-04-16 US US10/511,656 patent/US20050222061A1/en not_active Abandoned
- 2003-04-16 JP JP2003584309A patent/JP2006500910A/ja active Pending
- 2003-04-16 MX MXPA04010282A patent/MXPA04010282A/es not_active Application Discontinuation
- 2003-04-16 EP EP03718764A patent/EP1495120B1/en not_active Expired - Lifetime
- 2003-04-16 EP EP03720485A patent/EP1495121A2/en not_active Ceased
- 2003-04-16 US US10/511,657 patent/US8202845B2/en not_active Expired - Fee Related
- 2003-04-16 WO PCT/EP2003/004002 patent/WO2003087367A2/en not_active Ceased
- 2003-04-16 CA CA002482903A patent/CA2482903A1/en not_active Abandoned
- 2003-04-16 MX MXPA04010283A patent/MXPA04010283A/es not_active Application Discontinuation
- 2003-04-16 WO PCT/EP2003/004003 patent/WO2003087368A2/en not_active Ceased
- 2003-04-16 JP JP2003584308A patent/JP5578388B2/ja not_active Expired - Fee Related
- 2003-04-16 AU AU2003222820A patent/AU2003222820A1/en not_active Abandoned
- 2003-04-16 ES ES03718764T patent/ES2397060T3/es not_active Expired - Lifetime
- 2003-04-16 AU AU2003224087A patent/AU2003224087B2/en not_active Ceased
- 2003-04-16 CA CA002482904A patent/CA2482904A1/en not_active Abandoned
-
2009
- 2009-02-23 AU AU2009200699A patent/AU2009200699A1/en not_active Abandoned
-
2010
- 2010-07-01 US US12/828,624 patent/US20110021605A1/en not_active Abandoned
-
2012
- 2012-06-11 US US13/493,690 patent/US8946180B2/en not_active Expired - Fee Related
-
2014
- 2014-12-19 US US14/577,251 patent/US20150105448A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Holcomb et al. | FIZZ1, a novel cysteine‐rich secreted protein associated with pulmonary inflammation, defines a new gene family | |
| JP6258197B2 (ja) | 網膜疾患の治療方法 | |
| CN109646668B (zh) | 一种多肽用于制备防治阿尔茨海默病药物的用途 | |
| CN111956658B (zh) | miRNA 148簇作为诊断和/或治疗认知障碍相关疾病标志物的应用 | |
| EP2167692B1 (en) | Cd44 splice variants in neurodegenerative diseases | |
| JPH10117789A (ja) | ヒトセリンプロテアーゼ | |
| JPH08502168A (ja) | ニューロン細胞においてイオンチャンネル誘導活性をもつ栄養因子 | |
| WO2001066719A1 (fr) | Nouveau gene clone en neuroblastome humain et nouveaux fragments de gene | |
| KR102127218B1 (ko) | 뇌 신경 교종 치료용 약물 제조에서의 화합물의 용도 | |
| TW202221119A (zh) | Dna結合域轉活化子及其用途 | |
| JP2001500743A (ja) | ヒト片頭痛関連遺伝子 | |
| DE60316161T2 (de) | Neue kcnq-polypeptide und deren verwendung bei der diagnose von geisteskrankheiten | |
| KR101447560B1 (ko) | 인간 ｄｙｒｋ１ａ 유전자 형질전환 초파리를 이용한 치료제 스크리닝 방법 | |
| JPH03503410A (ja) | ヒト熱ショック因子 | |
| EP1428891A1 (en) | Novel gene nedl-1 | |
| US6962985B2 (en) | Mammalian neuralized family transcriptional regulators and uses therefor | |
| KR20220046965A (ko) | Smug1 유전자 또는 단백질을 포함하는 망막질환 예방 또는 치료용 조성물 | |
| JP2002533099A (ja) | 差次的遺伝子発現を用いる向精神薬剤を同定する方法 | |
| JP2002543833A (ja) | 海馬で発現する分子 | |
| EP1445315B1 (en) | Human and mammalian stem cell-derived neuronal survival polypeptides | |
| JP2001512679A (ja) | ヒトグリア細胞株由来神経栄養因子プロモーター、該プロモーターを含むベクター、および該プロモーターによる化合物のスクリーニング方法 | |
| US20040266677A1 (en) | Method of diagnosing and treating lens illnesses using human HSF4 gene and coded product thereof | |
| JPH11206391A (ja) | ヒトｌｉｇ−１相同体（ｈｌｉｇ−１） | |
| EP2128267A2 (en) | Methods of evaluating phosphatase inhibitors | |
| JP2006327951A (ja) | 双極性感情障害、統合失調症等の精神病性障害の予防・治療剤、そのスクリーニング方法、及び該疾患の発症リスクの判定方法 |